For research use only. Not for therapeutic Use.
Selective and ATP-competitive Janus Kinase JAK1/JAK2 inhibitor, with IC50 to be 11 and 18 nM for JAK1 and JAK2 respectively and far less activity against other kinases, including JAK3 (IC50=155 nM). The free base, Momelotinib (Axon 1681) is also available.
Keywords: Momelotinib hydrochloride | Supplier | JAK1/2 inhibitor | CYT387 hydrochloride | CYT-387 | CYT 387 | CAS [1841094-16-3] | [1056634-68-4] | [1380317-28-1] | [1841094-17-4] | JAK-STAT Pathway | JAK | Inhibitor | Enzymes
| Catalog Number | I047729 |
| CAS Number | 1841094-16-3 |
| Molecular Formula | C23H22N6O2.HCl |
| Purity | ≥95% |
| Reference | A Pardanan et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009, 23, 1441–1445. JW Tyner et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010, 115(25), 5232-5240. S Verstovsek. Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program. 2009, 636-642. |
